Jardiance 10mg Tablet contains Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting SGLT2 in the proximal renal tubules, Empagliflozin reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels. Jardiance is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated its efficacy in reducing HbA1c levels, with additional benefits including modest weight loss and a reduction in systolic blood pressure. Furthermore, Empagliflozin has shown cardiovascular benefits, including a decreased risk of cardiovascular death in patients with established cardiovascular disease. The recommended dose is 10 mg once daily, which may be adjusted based on patient response and tolerance. Jardiance is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to Empagliflozin. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored for signs of volume depletion and renal function periodically. Jardiance should be used with caution in patients at risk of hypotension or electrolyte imbalance.